These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 31078739)

  • 21. Octenylsuccinate hydroxypropyl phytoglycogen enhances the solubility and in-vitro antitumor efficacy of niclosamide.
    Xie Y; Yao Y
    Int J Pharm; 2018 Jan; 535(1-2):157-163. PubMed ID: 29113805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Niclosamide: A career builder.
    Needham D
    J Control Release; 2024 May; 369():786-856. PubMed ID: 37544514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oral delivery of anticancer drugs: challenges and opportunities.
    Thanki K; Gangwal RP; Sangamwar AT; Jain S
    J Control Release; 2013 Aug; 170(1):15-40. PubMed ID: 23648832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Niclosamide: an established antihelminthic drug as a potential therapy against S100A4-mediated metastatic colon tumors.
    Helfman DM
    J Natl Cancer Inst; 2011 Jul; 103(13):991-2. PubMed ID: 21685360
    [No Abstract]   [Full Text] [Related]  

  • 25. Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs.
    Lam MS
    Pharmacotherapy; 2011 Feb; 31(2):164-92. PubMed ID: 21275495
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nanosponge Carriers- An Archetype Swing in Cancer Therapy: A Comprehensive Review.
    Osmani RA; Hani U; Bhosale RR; Kulkarni PK; Shanmuganathan S
    Curr Drug Targets; 2017; 18(1):108-118. PubMed ID: 26424399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial to investigate the safety and efficacy of orally applied niclosamide in patients with metachronous or sychronous metastases of a colorectal cancer progressing after therapy: the NIKOLO trial.
    Burock S; Daum S; Keilholz U; Neumann K; Walther W; Stein U
    BMC Cancer; 2018 Mar; 18(1):297. PubMed ID: 29544454
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nanoscale drug delivery for targeted chemotherapy.
    Xin Y; Huang Q; Tang JQ; Hou XY; Zhang P; Zhang LZ; Jiang G
    Cancer Lett; 2016 Aug; 379(1):24-31. PubMed ID: 27235607
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pH Dependence of Niclosamide Solubility, Dissolution, and Morphology: Motivation for Potentially Universal Mucin-Penetrating Nasal and Throat Sprays for COVID19, its Variants and other Viral Infections.
    Needham D
    Pharm Res; 2022 Jan; 39(1):115-141. PubMed ID: 34962625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possibilities of poly(D,L-lactide-co-glycolide) in the formulation of nanomedicines against cancer.
    Holgado MA; Alvarez-Fuentes J; Fernández-Arévalo M; Arias JL
    Curr Drug Targets; 2011 Jul; 12(8):1096-111. PubMed ID: 21443478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Designs and Developments of Fucoidan-based Formulations for Cancer Therapy.
    Tran PHL; Tran TTD
    Curr Drug Metab; 2019; 20(12):933-941. PubMed ID: 31589118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preparation, characterization, and cytotoxicity studies of niclosamide loaded mesoporous drug delivery systems.
    Pardhi V; Chavan RB; Thipparaboina R; Thatikonda S; Naidu V; Shastri NR
    Int J Pharm; 2017 Aug; 528(1-2):202-214. PubMed ID: 28596138
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress in Redirecting Antiparasitic Drugs for Cancer Treatment.
    Huang H; He Q; Guo B; Xu X; Wu Y; Li X
    Drug Des Devel Ther; 2021; 15():2747-2767. PubMed ID: 34188451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug delivery/imaging multifunctionality of mesoporous silica-based composite nanostructures.
    Chen Y; Chen H; Shi J
    Expert Opin Drug Deliv; 2014 Jun; 11(6):917-30. PubMed ID: 24746014
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antineoplastic mechanisms of niclosamide-loaded nanoparticles in human colorectal cancer cells].
    Zhirnik AS; Semochkina YP; Moskaleva EY; Krylov NI; Tubasheva IA; Kuznetsov SL; Vorontsov EA
    Biomed Khim; 2017 Mar; 63(2):132-138. PubMed ID: 28414284
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines.
    Jin G; Wong ST
    Drug Discov Today; 2014 May; 19(5):637-44. PubMed ID: 24239728
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer.
    Lin CK; Bai MY; Hu TM; Wang YC; Chao TK; Weng SJ; Huang RL; Su PH; Lai HC
    Oncotarget; 2016 Feb; 7(8):8993-9006. PubMed ID: 26848771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functionalized Magnetic Nanostructures for Anticancer Therapy.
    Teodor ED; Gatea F; Ficai A; Radu GL
    Curr Drug Targets; 2018 Feb; 19(3):239-247. PubMed ID: 26853321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repurposing medicinal compounds for blood cancer treatment.
    McCabe B; Liberante F; Mills KI
    Ann Hematol; 2015 Aug; 94(8):1267-76. PubMed ID: 26048243
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy.
    Piktel E; Niemirowicz K; Wątek M; Wollny T; Deptuła P; Bucki R
    J Nanobiotechnology; 2016 May; 14(1):39. PubMed ID: 27229857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.